ESMO Congress | Conference

Enhanced Post-Surgery Surveillance Not Linked to Longer OS in NSCLC

September 10th 2017

Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.

PD-1/IDO Combination Active in Advanced Melanoma

September 10th 2017

A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.

Neoadjuvant Nivolumab Reduces Tumor Size Regardless of HPV Status in Head and Neck Cancer

September 10th 2017

Two doses of nivolumab given about 1 month prior to surgery are well tolerated and reduces tumor size in about half of patients with squamous cell carcinoma of the head and neck.

Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer

September 10th 2017

The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.

Denosumab May Help Some With Bone Tumors Avoid Surgery

September 9th 2017

More than one-third of patients with resectable giant cell tumor of bone avoided surgery and nearly half had less morbidity with surgery when treated with denosumab (Xgeva).

Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC

September 9th 2017

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC

September 9th 2017

Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.

Binimetinib Adds to Encorafenib PFS Benefit for BRAF+ Melanoma

September 9th 2017

The combination of encorafenib and binimetinib demonstrated significant improvements in PFS compared with single-agent vemurafenib or encorafenib for patients with BRAF-mutant advanced melanoma.

Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone

September 9th 2017

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

September 9th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy

September 9th 2017

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Nivolumab Past One Year Improves Progression-Free Survival in Pretreated NSCLC

September 9th 2017

Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.

Durvalumab "Game-Changer" for Locally Advanced Lung Cancer

September 9th 2017

The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.

Frontline Osimertinib Doubles PFS for EGFR+ NSCLC

September 9th 2017

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer

September 8th 2017

Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.

Alectinib Highly Effective for ALK+ NSCLC With CNS Metastases

September 8th 2017

Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

November 30th 2016

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

October 20th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.